Form D · Biotechnology
Precipio, Inc.
New Haven, CT · CIK 0001043961
Offering snapshot reported Nov 20, 2017 · SEC filing
- Reported sold
- $811K Offering amount: $811K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 31, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 20, 2017 | Initial | $810,840 | No comparison | 4 | SEC filing |
| Jul 17, 2017 | Initial | $8,269,459 | No comparison | 3 | SEC filing |
| Jul 14, 2017 | Initial | $800,000 | No comparison | 6 | SEC filing |
| Jul 14, 2017 | Initial | $0 | No comparison | 45 | SEC filing |
| Jul 14, 2017 | Initial | $399,997 | No comparison | 3 | SEC filing |
| Apr 26, 2017 | Initial | $1,150,000 | No comparison | 5 | SEC filing |
| Jan 20, 2016 | Initial | $2,199,676 | No comparison | 5 | SEC filing |
| Jul 17, 2015 | Initial | $3,039,760 | No comparison | 2 | SEC filing |
| Jan 26, 2015 | Amendment | $1,675,000 | $925,000vs Jan 15, 2015 | 8 | SEC filing |
| Jan 15, 2015 | Initial | $750,000 | No comparison | 1 | SEC filing |
| Oct 27, 2014 | Initial | $2,375,000 | No comparison | 9 | SEC filing |
| Mar 14, 2014 | Initial | $7,000,000 | No comparison | 3 | SEC filing |
| Feb 6, 2013 | Initial | $8,300,000 | No comparison | 32 | SEC filing |
| Feb 13, 2012 | Initial | $22,000,000 | No comparison | 56 | SEC filing |
| Jan 13, 2012 | Initial | $3,000,000 | No comparison | 3 | SEC filing |
| Jan 10, 2011 | Initial | $6,000,000 | No comparison | 3 | SEC filing |
| Nov 14, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-299183
Source: Form D, filed Nov 20, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Cohen | Director |
| Mark P. Colonnese | Executive |
| Jeff Cossman | Director |
| Ilan Danieli | Director, Executive |
| Katrina Fahlin | Executive |
| Doug Fisher | Director |
| Brett Frevert | Executive |
| Carl Iberger | Executive |
| Paul Kinnon | Director, Executive |
| Doit L Koppler | Director |
| Doit L. Koppler Ii | Director |
| Doit L. Koppler, Ii | Director |
| Michael Luther | Director |
| Rodney S. Markin | Director |
| Robert M. Patzig | Director |
| Samuel Riccitelli | Director |
| Chad M. Richards | Executive |
| Leon F. Richards | Executive |
| Mark Rimer | Director |
| Antonius P. Schuh | Director |
| Mya Thomae | Director |
| John D. Thompson | Director |
| Craig J. Tuttle | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4 Science Park
New Haven, CT, 06511
New Haven, CT, 06511